Weekly Investment Analysts’ Ratings Changes for Moderna (MRNA)

Moderna (NASDAQ: MRNA) recently received a number of ratings updates from brokerages and research firms:

• 11/26/2024 – Moderna had its price target lowered by analysts at JPMorgan Chase & Co. from $59.00 to $45.00. They now have an “underweight” rating on the stock.
• 11/19/2024 – Moderna is now covered by analysts at Berenberg Bank. They set a “hold” rating and a $42.00 price target on the stock.
• 11/18/2024 – Moderna was upgraded by analysts at Hsbc Global Res from a “hold” rating to a “strong-buy” rating.
• 11/18/2024 – Moderna had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $69.00 price target on the stock, down previously from $115.00.
• 11/18/2024 – Moderna was upgraded by analysts at HSBC Holdings plc from a “hold” rating to a “buy” rating. They now have a $58.00 price target on the stock.
• 11/15/2024 – Moderna is now covered by analysts at Wolfe Research. They set an “underperform” rating and a $40.00 price target on the stock.
• 11/8/2024 – Moderna had its price target lowered by analysts at Barclays PLC from $125.00 to $111.00. They now have an “overweight” rating on the stock.
• 11/8/2024 – Moderna had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 11/4/2024 – Moderna had its price target lowered by analysts at JPMorgan Chase & Co. from $70.00 to $59.00. They now have an “underweight” rating on the stock.
• 10/24/2024 – Moderna had its price target lowered by analysts at UBS Group AG from $140.00 to $108.00. They now have a “buy” rating on the stock.
• 10/17/2024 – Moderna is now covered by analysts at Sanford C. Bernstein. They set a “market perform” rating and a $55.00 price target on the stock.
• 10/15/2024 – Moderna had its price target lowered by analysts at Jefferies Financial Group Inc. from $65.00 to $55.00. They now have a “hold” rating on the stock.

Moderna Price Performance

Shares of Moderna stock traded up $1.34 during mid-day trading on Thursday, reaching $43.39. 5,079,747 shares of the stock were exchanged, compared to its average volume of 4,898,290. The company has a market cap of $16.70 billion, a price-to-earnings ratio of -7.46 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $53.32 and a 200 day simple moving average of $92.28. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted ($1.39) EPS. On average, sell-side analysts predict that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders have sold 1,147 shares of company stock worth $76,245. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

A number of hedge funds and other institutional investors have recently made changes to their positions in MRNA. Lazard Asset Management LLC raised its position in Moderna by 81.4% during the first quarter. Lazard Asset Management LLC now owns 10,171 shares of the company’s stock worth $1,082,000 after acquiring an additional 4,563 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in shares of Moderna by 18.6% in the first quarter. B. Riley Wealth Advisors Inc. now owns 9,871 shares of the company’s stock valued at $1,020,000 after purchasing an additional 1,549 shares during the last quarter. iA Global Asset Management Inc. increased its holdings in shares of Moderna by 4.7% in the first quarter. iA Global Asset Management Inc. now owns 35,900 shares of the company’s stock valued at $3,826,000 after purchasing an additional 1,609 shares during the last quarter. LRI Investments LLC acquired a new position in shares of Moderna in the first quarter valued at $124,000. Finally, Swedbank AB acquired a new position in shares of Moderna in the first quarter valued at $3,315,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.